Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551693 · ClinicalTrials.gov registry record · Phase 2
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01551693 is a Phase 2 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 3 participants.
The verdict
NCT01551693, a Phase 2 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
STA9090 is a drug which inactivates or blocks the work of a protein called Heat Shock Protein 90 or HSP90. HSP90 is a protein that helps some molecules inside your cells to have the right shape. By stopping HSP90's activity, those molecules never get to have the right structure of be functional and they are destroyed. The investigators believe that if they stop the activity of HSP90, the rapidly dividing cells that are in your tumor(s) may slow down. In this research study the investigators are looking to see how well STA9090 works in stopping the spread of your melanoma.
Interventions
- DRUG STA-9090
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551693
The ClinicalTrials.gov registry entry for NCT01551693 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-9090 is the first listed.
NCT01551693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01551693 about?
NCT01551693 is a clinical study titled "STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma". STA9090 is a drug which inactivates or blocks the work of a protein called Heat Shock Protein 90 or HSP90. HSP90 is a protein that helps some molecules inside your cells to have the right shape. By stopping HSP90's activity, those molecules never get to have the right structure of be functional and ...
What is the current status of trial NCT01551693?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-09. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01551693?
The interventions under investigation include: STA-9090 (DRUG).
Who is sponsoring clinical trial NCT01551693?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.